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Strain MS14, exhibiting antifungal activity, was classified to belong to
Burkholderia contaminans. Occidiofungin produced by strain MS14 is an octapeptide
dedicated to a broad range of antifungal activities of the bacterium. The 58.2-kb genomic
fragment containing 18 open reading frames (ORFs), named occidiofungin (occ) gene
cluster, is required for occidiofungin production. Putative proteins encoded by five
nonribosomal peptide synthetase genes (occA – occE) of the gene cluster were predicted
to contain the catalytic modules responsible for the biosynthesis of occidiofungin.
Transcription of all the ORFs identified in the region except ORF1 and ORF16 was
regulated by both ambR1 and ambR2, the LuxR-type regulatory genes located at the left
border of the cluster. The functional ambR1 gene was essential for transcription of
ambR2, and constitutive expression of ambR2 did not restore the phenotype of the mutant
MS14GG44(ambR1::nptII). Sequence analysis revealed that the occ gene cluster shared
high similarity (99% nucleotide coverage and 91% identity) to an uncharacterized DNA
region of B. ambifaria strain AMMD. The gene cluster was not found in other
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Burkholderia strains available in GenBank (nucleotide coverage < 24%). Analysis of
G+C composition and prediction using “IslandPick” indicate that the occ gene cluster has
possibly been horizontally transferred between bacteria. In addition, the absence of the
gene cluster in clinical strains of Burkholderia indicates that occidiofungin is not required
for potential human pathogenesis. The findings have provided insights into the
development of antifungal medicines and agricultural fungicides based on occidiofungin.
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CHAPTER I
GENERAL INTRODUCTION
Biological control is the use of natural or modified organisms, genes, or gene
products, to reduce the effects of undesirable organisms such as plant pathogens and to
favor desirable organisms such as crops, and is an important component of integrated pest
management (11). It has recently inspired research and development due to the problems
associated with hazardous pesticides, such as the negative impact on the environment and
the heavy cost. Furthermore, research on novel biological control agents lays the
foundation for the development of commercialized products.
Pathogen- Suppressive Soils
Antagonistic microbes present in pathogen-suppressive soils are important
resources of genetic materials for developing transgenic crops and biopesticides.
Pathogen-suppressive soils were defined as the soils in which a soilborne pathogen does
not become established or causes little or no damage to the host plant (11). In agronomic
ecosystems, suppressive soils have been described for many soilborne disease systems,
such as the diseases caused by Gaeumannomyces graminis var. tritici, Pythium spp., and
Rhizoctonia solani (41). Bacterial species of the genera Pseudomonas, Bacillus,
Enterobacter, and Streptomyces as well as species of the fungal genera Trichoderma and
Gliocladium are frequently identified from suppressive soils (29). Therefore, the
suppressive soils, in which antagonistic microbes interact with the soilborne pathogens,
are important pools to search for useful genetic materials (17). Mechanisms of soil
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suppressiveness to soilborne pathogens are complex, which include antibiotic
biosyntheses, resource competitions, and hyperparasitisms (2,12,34,39). One of the bestdescribed examples is the take-all decline soil of wheat fields, in which fluorescent
pseudomonads producing antifungal phenazines are present (12). The production of the
phenazines was considered to be a key factor to suppress the growth of the take-all
pathogen G. graminis var. tritici. Some strains of Pseudomonas identified from the takeall decline soil have been used for biological control of plant diseases (28). However,
more studies on diverse disease ecosystems are needed to increase our understanding of
molecular activities of these antagonistic microorganisms and to provide more clues to
the development of biological-based strategies for disease management (41).
The Burkholderia Bacteria
The genus Burkholderia was erected by Yabuuchi et al. in 1992 to accommodate
a few species of Pseudomonas that belongs to the rRNA group II (42). Currently, the
genus contains 34 validly described species (9). The bacteria of this genus are attracting
considerable attention for its extraordinary versatility as plant pathogens, saprophytes,
biocontrol agents, bioremediation agents, and human pathogens (7). Unlike other groups
of bacteria, the 16S rDNA sequences of the Burkholderia species have significantly high
identities (> 98%) and are not sufficiently discretionary to resolve all the species (26).
Instead, nucleotide sequence information of the recA gene was successfully used to
differentiate the Burkholderia species from the closely related bacteria and to sort the
Burkholderia isolates into species (8,27,32). Recently, a polyphasic taxonomic approach
using multiple analyses was proposed for identification of species of the species and
typing of strains of Burkholderia (4).
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A number of Burkholderia strains have been reported as plant-growth-promoting
bacteria as free-living in rhizosphere, epiphytic, or endophytic microorganisms (7,10,31).
Several species of Burkholderia were successfully used as biological control agents for
managing economically important fungal plant diseases (7). For example, some strains
of Burkholderia showed significant antagonistic activity against plant pathogens and
were commercially registered as biocontrol products, such as “DENY” and “Blue Circle”
(http://www.apsnet.org/education/feature/BurkholderiaCepacia/). Some strains of
Burkholderia, however, were reported to be associated with cystic fibrosis human disease
as opportunistic pathogens (26). Unfortunately, taxonomic distinctions have not enabled
biological control strains to be clearly distinguished from human pathogenic strains,
which has led to a reassessment of the risk of several strains registered by the U.S.
Environmental Protection Agency for biological control (31). Therefore, understanding
the molecular mechanisms of these bacteria with effectiveness in managing plant diseases
might provide important clues to developing biological-based strategies for antifungal
applications and to eliminate the potential risk the bacteria may bring.
Antifungal Compounds Produced by the Burkholderia Bacteria
Efforts on characterization of chemical structures and genetic information of
antifungal compounds have extensively been taken. The antifungal compounds produced
by Burkholderia bacteria, which have been identified so far, include: cepalycin (1),
cepacidine A (23), pyrrolnitrin (18), xylocandin complex (30), CF66I (33), and AFCBC11 (21).
Cepalycin produced by B. cepacia JN106 was identified as a hemolytic antifungal
substance, whose chemical composition is unknown (1). It was reported that cepalycins
3

could interact with cholesterol in erythrocyte membrane, which might contribute to their
hemolytic and antifungal activities.
Cepacidine A produced by B. cepacia AF 2001 was identified as a glycopeptide
compound comprised of eight amino acids, including one glycine, two serine, one 2,4diaminobutyric acid, one aspartic acid, one β-hydroxy tyrosine, one β-hydroxy
asparagine, one xylose and one 5,7-dihydroxy-3,9-diaminooctadecanoic acid (23) (Fig.
1.1). It was reported that cepacidine A is a mixture of A1 and A2, and the difference
between them is that cepacidine A2 includes one asparagine instead of one β-hydroxy
asparagine in cepacidine A1.

Figure 1.1

Structure of cepacidine A
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Pyrrolnitrin produced by B. cepacia NB-1 was identified as C10H6Cl2N2O2 (18).
It can block the electron system, which was relieved by N, N, N, N, tetramethyl-pphenylenediamine dihydrochloride (TMPD) (Fig. 1.2).

Figure 1.2

Structure of pyrrolnitrin

Xylocandin complex produced by B. cepacia ATCC 39277 was identified as a
cyclic peptide containing glycine, serine, asparagine (1-3 residues), beta-hydroxytyrosine,
and an unusual amino acid with the formula C18H37N2O5 (5).
CF66I produced by B. cepacia CF66 was confirmed to have amide bonds, ametyl fatty acid, bromine, and some structural units such as CH2CH2O (33). It was
reported that CF66I was stable to high temperature, proteolytic enzymes, and organic
solvents, and it could inhibit the growth of a variety of plant pathogenic fungi and
pathogenic yeast, whereas bacterial cells are unaffected.
AFC-BC11 produced by strain B. cepacia BC11 was predicted to be a
nonribosomally synthesized lipopeptide (21). One of the genes required for biosynthesis
of AFC-BC11 was partially characterized (21).
Biosyntheses of Antifungal Compounds in Burkholderia
Among these antifungal compounds, only cepacidine A, xylocandin complex and
AFC-BC11 were characterized or predicted to be oligopeptides. Only the genes required
5

for biosynthesis of AFC-BC11 and pyrrolnitrin were partially characterized; while the
genes for production of the rest of substances remain to be characterized. Few genetic
elements that are responsible for antimicrobial activities of the Burkholderia strains have
been characterized. A major limitation for the genetic analysis of the biological functions
of the bacteria is that tools for genetic manipulations and analysis are much less well
developed because most strains of Burkholderia possess inherent resistance to many
antibiotics and lower frequencies of the introduction of foreign plasmids by both
electroporation and conjugation (20). In addition, the genomes of the species of
Burkholderia are much larger and more complicated than those of pseudomonds because
each genome of the bacteria is composed of multiple replicons (23).
N-acyl homoserine lactones (AHLs) synthesized by AHL synthases in B.
ambifaria BC-F were identified as signal chemicals interacting with transcriptional
regulators of the LuxRI family (43). It was reported that the AHL-deficient mutants of B.
ambifaria BC-F at AHL synthase gene (bafI) and AHL-binding transcriptional activator
gene (bafR) positions had decreased antifungal activity.
Nonribosomal peptides, as a class of peptide secondary metabolites, are
synthesized by NRPS, which, unlike the ribosomes, are independent of messenger RNA
(38). Nonribosomal peptide synthetase typically is a large multimodular enzyme
involved in oligopeptide biosynthesis. NRPSs are grouped by active sites termed
modules, in which each module is required for catalyzing one single cycle of product
length elongation (Fig. 1.3). Nonribosomal machinery for peptide synthesis is usually
composed of more than one NRPS modules, which form a multienzyme complex as an
assembly line to catalyze stepwise peptide condensation. The order and number of the
modules of an NRPS protein are, in many cases, collinear to the amino acid sequence of
6

the corresponding peptide moiety of the final molecule (‘collinearity rule’) (16) . Each
module of the NRPSs can be further subdivided into domains, each of which exhibits a
single enzymic activity. The adenylation (A) domain is responsible for amino acid
recognition and adenylation at the expense of ATP. The thiolation (T) or peptidyl carrier
protein domain is the attachment site of the 49-phosphopantetheine cofactor and serves as
a carrier of thioesterified amino acid intermediates. The condensation (C) domain
catalyses peptide bond formation between two consecutive amino acids. Modifying
domains such as the epimerization (E) domain catalyse the conversion of L-amino acids
to their D-isomers. Finally, cyclization and release of the peptide product are catalysed by
the C-terminal thioesterase (Te) domain. Thioesterase domains often occur integrated in
or associated with peptide synthetases which are involved in the non-ribosomal synthesis
of peptide antibiotics (39). Thioesterases are required for the addition of the last amino
acid to the peptide antibiotic, thereby forming a cyclic antibiotic (6). Many
pharmaceutical antimicrobial agents are biosynthesized via NRPS systems, such as
penicillin precursor and vancomycin (40). Common to NRPS assembly lines are the
incorporation of nonproteinogenic amino acids, such as D-amino acids and carboxy acids
(38). Sequence analyses of catalytic modules of NRPSs are frequently used for product
prediction (35).
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Figure 1.3

Basic steps during non-ribosomal peptide synthetase

Polyketide synthetases (PKS) are a family of enzymes or enzyme complexes that
produce polyketides, a large class of biologically active molecules, in bacteria, fungi,
plants, and a few animals lineages (22). The biosyntheses of PK share striking
architectural and organizational similarities with NRP biosynthesis with the building
block of propionyl-CoA or methylmalonyl-CoA instead of amino acid. Several classes of
PKS genes are commonly recognized (22). Type I PKS are large, multidomain enzymes
carrying a series of functional sites for stepwise polyketide synthesis. Type II PKS are
composed of three or more enzymes, which act in an iterative manner during synthesis. A
core of three enzymes referred to as the minimal PKS is shared by all pathways: the Acyl
transferase (AT) domain, the Acyl carrier protein (ACP) domain, and the Ketosynthase
(KS) domain (Fig. 1.4). Polyketides are structurally diverse secondary metabolites that
have already found widespread application as pharmaceuticals, such as erythromycin
(13).

8

Figure 1.4

Basic steps during polyketide synthetase

The modules of NRPS and PKS can be integrated to produce the hybrid NRPSPKS products (3), such as bleomycin produced by the Streptomyces verticillus and
gramacidin S produced by Bacillus brevis.
LuxR-type regulators, which contains DNA-binding, helix-turn-helix (HTH)
domains at their C termini, are conserved and common proteins in bacteria (14,19,25).
These LuxR type regulators control a wide variety of biological functions, including
production of secondary metabolites, such as NRPS-PKS products. Based on their
functional mechanisms, these LuxR type proteins are grouped into two major
subfamilies: response regulators and autoinducer-binding regulators (19).
Significance of the Study
In this research, a few isolates with significant antifungal activity were isolated
from agricultural soils of Mississippi. Evidence from morphology, biochemistry and
DNA sequence analysis revealed that one of the isolates, named as MS14, was
characterized to belong to B. contaminans. Strain MS14 is predicted to produce a novel
9

oligopeptide antifungal compound via a hybrid nonribosomal peptide synthetase (NRPS)
and polyketide synthetase (PKS) system.
This study reveals that the occ gene cluster is responsible for the production of
antifungal compound of strain MS14, which has provided a firm base for characterizing
the biosynthesis and chemical composition of the antifungal compound produced by
strain MS14. This work has also provided important clues for development of
pharmaceutical medicines and agricultural fungicides.

10
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CHAPTER II
BIOSYNTHESIS OF AN ANTIFUNGAL OLIGOPEPTIDE IN BURKHOLDERIA
CONTAMINANS STRAIN MS14
Introduction
The Burkholderia cepacia complex (Bcc) was composed of nine validly named
species of Burkholderia, which are genetically different but phenotypically similar
bacteria (4). Recently, the descriptions of an additional eight novel species have
increased the number of Bcc species to seventeen (24) including B. contaminans (23).
Nucleotide sequences of the recA genes have been used to differentiate the Burkholderia
species and all members of the B. cepacia complex (16).
A striking feature of some strains of Burkholderia is production of various
antifungal compounds, which can be used for fungal disease management (4). However,
their use for fungal disease management was reconsidered, since they were shown to be
opportunistic pathogens associated with the human disease cystic fibrosis (15).
Understanding the molecular mechanisms of antifungal activities of the Burkholderia
strains will provide important clues for the development of biological-based fungicides,
while eliminating potential health risks. However, few genetic elements responsible for
antimicrobial activities of Burkholderia have been characterized, particularly due to
genetic analysis limitations of the biological functions of the bacteria. Some strains have
an inherent resistance to many antibiotics and the development of genetic analysis tools
had been lacking (10). The development of the Tn5 transposition complexes (8), as well
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as the Burkholderia expression vectors (12) has enabled the characterization of genes of
interest more efficiently.
Strain MS14 showed a broad range of antifungal activities to plant and human
fungal pathogens (14). In this study, the bacterium was classified to belong to B.
contaminans, and a 22.7-kb genetic locus was demonstrated to be required for the
antifungal oligopeptide biosynthesis.
Materials and Methods
Culture condition and media
Nutrient broth-yeast extract (NBY) (9) was used to culture strains of
Burkholderia. Potato dextrose agar (PDA) and potato dextrose broth (PDB, Difco
Laboratories Inc., Detroit MI) were used for plate bioassays of Burkholderia strains for
antifungal activity and for isolation of antifungal compounds, respectively. When
required, antibiotics were added at the following concentrations: trimethoprim (50 µg ml1

) and kanamycin (100 µg ml-1 for E. coli and 300 µg ml-1 for the MS14 mutants).

Assays of antifungal activities
Antifungal activities of strain MS14 and its mutants were evaluated using the
PDA plate bioassays described previously (22). Geotrichum candidum F-260 (9) was
used as a indicator fungus for the assays. Fractions from the reverse phase-high
performance liquid chromatography (RP-HPLC) run were dried in a speedvac at room
temperature and resuspended in an equal volume of water. The bioactivity of the
fractions was measured routinely using a fungicide assay method (5).

17

Cloning and sequence analysis of the 16S rRNA and recA genes
Extraction of bacterial genomic DNA was performed using the cetyl trimethyl
ammonium bromide protocol (3). Primers Bu16SF and Bu16SR (Table 2.1) were used to
amplify the 16S rRNA gene of strain MS14 using a routine PCR procedure (20). The
same PCR procedure was conducted for the recA PCR amplification with primers BCR1
and BCR2 as described previously (16) except using Vent DNA polymerase (New
England Biolabs, Beverly, MD). After adenylation, the PCR products were ligated into
pGEM T-Easy vector as recommended by the manufacturer (Promega Corp., Madison,
WI). Sequencing reactions were run on a CEQ 8000 genetic analysis system (Beckman
Coulter, Inc., Fullerton, CA). The Lasergene software package (DNASTAR, Inc.,
Madison, WS) was used for sequence analysis.
Mutagenesis analysis
To characterize the genes dedicated to antifungal activity, strain MS14 was
randomly mutated using an EZ-Tn5 <R6Kγori/KAN-2>Tnp Transposome kit as
recommended by the manufacturer (Epicentre Biotechnologies, Madison, WI). Insertion
of the EZ::TN transposon conferred resistance to kanamycin at 300 µg ml-1 supplemented
on NBY plates, enabling selection of mutant candidates. The mutants that were defective
or reduced significantly in antifungal activity against G. candidum were further streaked
on NBY plates for further analysis. To confirm that the resulting mutants were
derivatives of strain MS14, the recA genes were cloned and sequenced as described
above. The single insertion of the transposon into the genome of each resulting mutants
was verified by Southern blotting analysis using the nptII gene fragment (13). The DNA
fragments targeted by the transposon in each of the mutants were cloned using a plasmid
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rescue procedure as recommended by the manufacturer of the EZ-Tn5 kit. Sequencing
reactions were performed using the primers supplied in the kit.
Construction of a genomic library of strain MS14, library screening, and DNA
sequencing
To characterize the intact genes of interest, a genomic library of strain MS14 was
constructed using the CopyControl HTP Fosmid library production kit as recommended
by the manufacturer (Epicentre Biotechnologies). To identify the clones harboring the
gene fragment of interest, the genomic library was screened using a 0.4-kb PCR product,
which carries the partial gene transposon-targeted in mutant MS14MT15, following a
routine colony hybridization protocol (20). The 0.4-kb PCR product was amplified from
100 ng plasmid pSL615 (see description in Results and Discussion) using a GoTaq PCR
Core kit (Promega) with primers R6KAN-2RP-1 and KAN-2FP-1 provided in the
EZ::TN transposon kit. The DNA insert of fosmid 5F12 identified from the library was
sequenced by using a EZ-Tn5-based sequencing approach (21). At least triple coverage
of sequencing reactions was achieved, and a consensus sequence was generated with the
SeqMan program in the Lasergene software package, and the resulting sequence was
deposited into the GenBank database with accession number: EU938698. The program
BLAST (2) was used to identify nucleic acid and protein homologies. InterProScan
program was used for prediction of functional domains and signatures of proteins (18).
NRPSpredictor was used for specificity prediction of adenylation domains in
nonribosomal peptide synthetases (NRPSs) (19).
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Complementation of mutant MS14MT15
To obtain the intact wild type gene ambR2, which was disrupted in mutant
MS14MT15, a 1.9-kb BamHI fragment of the fosmid 5F12 was subcloned into
pBlueScript SK (+) generating plasmid pGG1. The presence of the intact ambR2 gene in
the 1.9-kb DNA fragment was verified by sequencing. The 1.9-kb BamHI fragment
harboring the intact ambR2 gene was inserted into the Burkholderia gene expression
vector pMLS7 (12), to generate plasmid pGG2. Plasmid pGG2 were electroporated into
cells of mutant MS14MT15. The empty vector was used as a control. Colonies
acquiring the trimethoprim resistance were confirmed to contain the plasmid construct
pGG2 by sequencing. Complementation experiments were conducted using the plate
assays to evaluate antifungal activity against G. candidum.
RNA extraction and quantitative real-time PCR
Real time PCR analysis of the ORF5 expression indicated that the maximum level
of RNA was present in MS14 growing in 100 mL of PDB for 72 hr after inoculation at
28°C without shaking. Consequently, RNAs were extracted under this condition for gene
expression analyses. Total RNA of bacterial cells was isolated using an RNeasy Protect
Bacteria kit (Qiagen, Valencia, CA) as recommended by the manufacturer. The OneStep QuantiTect SYBR green RT-PCR kit (Qiagen) was used with primers (Table 2.1)
for each gene. The CT values of the ORFs used to determine transcript levels were
normalized by housekeeping gene recA as follows: ΔCT = CT(tested) – CT(recA). The relative
quantification (RQ) values were calculated by the formula RQ = 2[ΔCT(mutant) – ΔCT(wild type)] . As
described previously (6), if transcript levels of the wild type and the mutant have no
differences, RQ = 1 and log RQ = 0. Three replicates of RT PCR analysis for each
reaction were performed independently. Statistical significant differences were
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determined for RQ values by analysis of variance (P < 0.05) followed by the Bonferroni
and Dunnet post hoc multiple comparisons (ANOVA, SAS Institute, Inc., NC, USA).
Isolation of antifungal compound
The wild type strain MS14 (200 µl at 4×107 CFU ml-1) was inoculated into 100 ml
PDB and incubated at 28oC for 4 days without shaking. The mutant MS14MT18 was
used as a control, since it lacks antifungal activity. Ammonium sulfate (AS)
precipitations (50% w/v) were done using 30 ml of the cell free culture liquor on ice for 2
hours. Following the AS precipitation, supernatants were centrifuged at 10,000 × g for
20 minutes. The pellets were resuspended in 1 ml of 35% acetonitrile (ACN):water (v/v)
and placed in a 1.5 ml microcentrifuge tube. RP-HPLC was done using a 4.6 × 250 mm
C18 column (Grace-Vydac, catalog 201TP54) on a Bio-Rad BioLogic F10 Duo Flow
with Quad Tec UV-Vis Detector system. Matrix-Assisted Laser Desorption/Ionization
Mass Spectrometry – Time of Flight (MALDI-TOF, ABI 4700 Proteomics Analyzer) was
used to determine the mass of peaks that weren’t in common to MS14MT18 RP-HPLC
fractions. Amino acid analysis was performed at the Molecular Structure Facility, UC
Davis. The bioactivity of these fractions was determined using the antifungal bioassay
described above.
Results and discussion
Classification of strain MS14
A nearly full length of the 16S rRNA gene sequence was determined for strain
MS14 (GenBank accession no. EU938697), and shared the highest identities (98.099.7%) to those of the Burkholderia species. A 1,003 bp PCR fragment carrying the recA
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gene of strain MS14 was obtained and sequenced (GenBank accession no. EU938696).
Sequence analysis revealed that the nucleotide sequence of the recA gene of strain MS14
was identical to those of both B. contaminans (vanimaris) R-9896 (GenBank accession
no. AM905036) and B. contaminans (cepacia) R-9929 (Elke Vanlaere, personal
communication; GenBank accession no. AF456020) (23). The results suggest that strain
MS14 is a member of the species B. contaminans. Strains characterized in the species
were primarily isolated from cystic fibrosis patients, as well as sheep milk (23). Strain
MS14 was isolated from plant rhizosphere, which has expanded the distribution of B.
contaminans.
Identification of three genes involved in production of the antifungal product
From three transposition events using the EZ-Tn5 transposon system
approximately 8,600 kanamycin resistant colonies were obtained and then tested for
antifungal activity against G. candidum. From the preliminary screening, it was found
that the antifungal activity of three mutants of strain MS14 were reduced (MS14MT15)
or eliminated (MS14MT13 and MS14MT18). As compared with the wild type MS14,
antifungal assays revealed that mutants MS14MT13 and MS14MT18 were defective in
antifungal activity against the indicator fungus G. candidum, and the antifungal activity
of mutant MS14MT15 was reduced by approximately 80% (Fig. 2.1I). The three mutants
also showed the same patterns of antifungal activity against R. solani (data not shown).
Three plasmids pSL613, pSL615 and pSL618 were obtained from the genomes of
mutants MS14MT13, MS14MT15 and MS14MT18, respectively, using the plasmid
rescue method. Plasmids pSL613, pSL615 and pSL618 carry 0.3 kb, 0.5 kb and 2 kb
genomic DNA inserts, respectively. The genes targeted by the transposon were cloned
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and partially sequenced. BLAST analyses revealed that the disrupted genes of the
mutants MS14MT13, MS14MT15, and MS14MT18 shared high identities to bamb_6472,
bamb_6468, and bamb_6473, respectively, in an uncharacterized DNA region of B.
ambifaria AMMD (GenBank accession no. NC_008392).
Sequence analysis of the gene region responsible for production of the antifungal
product
Assembling sequencing reads generated a 22.7-kb DNA sequence contig from the
fosmid 5F12. The nucleotide sequence including putative proteins was deposited in
GenBank (Accession number: EU938698). Sequence analysis revealed the presence of
six potential ORFs in the region (Fig. 2.2). Genetic organization and transcriptional
orientations of the predicted ORFs in the DNA region are the same as those of strain
AMMD. The six proteins predicted in the DNA region have an averaged identity of
86.7% to those of strain AMMD (Table 2.2).
The ambR2 gene was predicted to start with an ATG translation initiation codon
that is preceded by a putative Shine-Dalgarno sequence (AGGA), and it codes for a 296residue protein. Database search showed that the full length AmbR2 protein had strong
amino acid identity (77%) to the protein Bamb_6468, a putative LuxR regulator of strain
AMMD. Alignment analysis of the DNA sequence previously obtained with the plasmid
rescue method revealed that the transposon in the mutant MS14MT15 genome was
inserted within the ambR2 gene between nucleotides 254 and 255 relative to its start
codon.
Putative protein sequences of the ORFs 5 and 6 are 3165 and 3022 amino acids in
length, respectively. Both proteins shared significant identities to two NRPSs produced
by a gene cluster in the genome of strain AMMD. ORF5 was predicted to have two
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NRPS catalytic modules for asparagine and serine, followed by a thioesterase domain at
the C terminus (a.a. 2,892-3,159; E score: 2.3e-23). ORF6 was predicted to have two
catalytic modules of NRPS, however, no amino acid matches from the database were
found. These results suggest that the two NRPS genes contribute to catalyzation of four
amino acid residues of an unknown oligopeptide. Sequence analysis revealed that the
transposons in the genomes of mutants MS14MT13 and MS14MT18 were located
between nucleotides 7,336-7,337 of ORF5 and 4,648-4,649 of ORF6, respectively,
relative to their translational start codons. These mutations resulted in a complete loss of
antifungal activity.
NRPS genes are widely distributed in the bacterial genomes and frequently
clustered together with transcriptional regulator genes and transporter genes (6,13). The
NRPS contribute to biosynthesis of oligopeptides or oligopeptide-based metabolites
including various antibiotics (17). The findings of this study suggest that the antifungal
compound of MS14 is an oligopeptide synthesized via a nonribosomal peptide synthetase
mechanism.
Characterization of AmbR2’s role in the production of the antifungal product
The ambR2 gene targeted in the transposon mutant MS14MT15 was further
characterized to determine the gene’s direct role in antifungal production. Introduction of
plasmid pGG2, carrying the wild type ambR2 gene, into the mutant complemented the
mutation in trans. Mutant MS14MT15 harboring plasmid pGG2 was as inhibitory to G.
candidum as the wild type strain MS14 (12.0 ± 1.0 mm in radius) (Fig. 2.1II). In
contrast, mutant MS14MT15 carrying the empty vector pMLS7 had the same antifungal
activity as the mutant (2.7 ± 1.2 mm in radius). Furthermore, the presence of the empty
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vector pMLS7 had no effect on antifungal activity of the wild type strain MS14 (data not
shown). These results show that ambR2 plays a direct role in production of antifungal
activity of MS14.
To test whether a mutation in ambR2 affected expression of other ORFs in the
region, quantitative real-time PCR analyses were performed with RNAs isolated from the
wild type strain MS14 and MS14MT15. Significant decreases (P < 0.05) of expression
levels of ORFs 2-6 in MS14MT15 were observed as compared with those in the wild
type strain MS14. Transcript levels of the ORFs in MS14MT15 (as compared with the
wild type MS14) were reduced 11.5 folds on average (Fig. 2.3). These data reveal that
ambR2 gene product acts to promote, either directly or indirectly, transcription of ORFs
2-6.
Isolation of antifungal compound produced by strain MS14
The mutant MS14MT18 was used as a control for the isolation of the antifungal
compound by RP-HPLC, since it lacks antifungal activity to the indicator fungus G.
candidum. As seen in Fig. 2.4, mutant MS14MT18 (gray) lacked peaks that were present
in the wild type strain MS14 (black). Further analysis indicated that a doublet peak in the
RP-HPLC chromatogram exhibited strong antifungal activity to the indicator fungus (data
not shown). The antifungal compound eluted from the column at 37% water:ACN 0.1%
TFA (v/v). The molecular weights of the purified compound were determined to be
1200.6 Da and 1216.6 Da. Presumably this mass difference of 16 Da is attributed to an
oxidized variant of the antifungal compound. An additional peak found in the AS
precipitant of MS14, not MS14MT18, was isolated, and determined to have no antifungal
activity and a mass of 1072.8 and 1088.8 Da. Possibly this peak could be a variant of the
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antifungal compound that has not undergone complete processing, since it also appears to
vary by 16 Da. Amino acid analysis of the purified bioactive peak revealed that the
antifungal compound consists of asparagine or aspartic acid, glycine, lysine, and serine
residues. Composition of serine and asparagine is consistent with the catalytic modules
of the NRPS predicted in ORF5. These data further suggest the antifungal compound is
an oligopeptide-based product.
To date, only a few (full or partial) chemical compositions of antifungal
compounds produced by Burkholderia have been reported, such as cepalycin (1),
cepacidine A (11), pyrrolnitrin (7), and AFC-BC11 (10). In addition, the genes required
for these products were partially (AFC-BC11) or fully (pyrrolnitrin) characterized.
Sequence analysis revealed that the DNA regions of MS14 shared the highest nucleotide
identity (90.4%) to the genes in an uncharacterized region of strain AMMD.
Interestingly, the product of the AMMD gene cluster has not been characterized. Taken
together, the genomic locus identified in this study is a novel genetic element dedicated
to biosynthesis of antifungal compound.
Conclusions
This study reveals that a genetic locus is responsible for the production of
antifungal compound by strain MS14. Mutagenesis and bioassays demonstrate that the
two NRPS genes (ORFs 5 and 6) contribute to the biosynthesis of the antifungal
compound. The transcription of the two genes is regulated by ambR2, which encodes a
putative LuxR type regulator. Further sequence analysis of the genes and preliminary
chemical analysis indicate that the backbone of the antifungal compound is an
oligopeptide that is synthesized via a NRPS mechanism. The study provides a firm base
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for future work aimed at characterizing the production and chemical composition of the
antifungal compound. Currently, sequencing of the whole genomic region associated
with the antifungal activity of MS14 is under way, as well as the elucidation of chemical
structure of the compound. This work will provide important clues for development of
pharmaceutical medicines or agricultural fungicides.
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Table 2.1

Primers used in this study

Primer

Sequence (5’-3’)

AmbR2F

5'-CCGCGGCGATCAGGTTGTA

AmbR2R

5'-CATGGAGTTCAGCAGATTGTTCGC

ORF2F

5'-GACTTTCATGCAGGCATAGGAGGG

ORF2R

5'-GATGATCGCCAGACGCTGTTGC

ORF3F

5'-CGGCGACGCGATTTCACTG

ORF3R

5'-CGGGGATTGCTTTCGATGCTG

ORF4F

5'-GAAGTGATACGCGCCCAGGAAC

ORF4R

5'-CATCTCGCCGCGGTGAAACA

ORF5F

5'-GTCGGTGACCAGCACGTTATTGT

ORF5R

5'-GTGCGTGCTGCTTCAGGTTGTT

ORF6F

5'-ACCCGTCGAGCAGGATGTGGT

ORF6R

5'-CGCGGCTTCGACTTTACCC

RecAF

5'-AAGATCGGCCAGGGCAAGGA

RecAR

5'-ACCATCGGGCATCGTGACCA

Bu16SF

5’-AGAGTTTGATCCTGGCTCAG

Bu16SR

5’-TACGGCTACCTTGTTACGACTT
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Table 2.2

The putative genes identified in the ambR2 region

Gene or
ORF
ambR2

Size
(bp)
891

bamb_6468

Identity
(%)
77

LuxR-type regulator

ORF2

1704

bamb_6469

90

Cyclic peptide transporter

ORF3

483

bamb_6470

82

Hypothetic protein

ORF4

657

bamb_6471

94

Glycosyl transferase

ORF5

9495

bamb_6472

88

ORF6

9066

bamb_6473

89

Homologue a

Predicted Function b

Nonribosomal peptide
synthetase
Nonribosomal peptide
synthetase

a: Homolog to the putative proteins of Burkholderia ambifaria AMMD (GenBank
accession no. NC_008392); b: Predicted functions are based on annotation of strain
AMMD.
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Figure 2.1

Plate bioassays of antifungal activities of Burkholderia contaminans MS14.

Plate bioassays of antifungal activities of Burkholderia contaminans MS14 with its
mutants against the indicator fungus Geotrichum candidum. (I) Mutants of strain MS14.
A: the wild type strain MS14; B: MS14MT13; C: MS14MT15; and D: MS14MT18. (II)
Complementation of the mutant MS14MT15. A: the wild type strain MS14; B:
MS14MT15; C: MS14MT15 (pGG2); and D: MS14MT15 (pMLS7).
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Figure 2.2

Gene organization of a 22.7-kb genomic region on the chromosome of
Burkholderia contaminans MS14.

Vertical arrows indicate the insertion positions of the Tn5 transposon. The open and
solid vertical arrows represent reduction and elimination of antifungal activity,
respectively.
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Figure 2.3

Expression of the ORFs identified in the genetic locus in the mutant
MS14MT15.

Transcript levels of the tested ORFs are presented relative to the transcript levels in the
wild type MS14. Mean values for three biological replicates are given, and error bars
represent the standard errors of the means.
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Figure 2.4

Overlaid RP-HPLC chromatogram for the extraction of antifungal
compound producted by Burkholderia contaminans strain MS14.

Overlaid RP-HPLC chromatogram obtained from the extracts from both the wild type
strain MS14 (black) and mutant strain MS14MT18 (gray). A doublet peak, which is
unique to MS14, was determined to be the antifungal compound.
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CHAPTER III
AMBR1 IS A KEY TRANSCRIPTIONAL REGULATOR FOR PRODUCTION OF
ANTIFUNGAL ACTIVITY OF BURKHOLDERIA CONTAMINANS STRAIN MS14
Introduction
Burkholderia bacteria are frequently isolated from the rhizosphere of crops, and
are involved in growth promotion of plants and suppression of plant diseases (3,13).
However, biological control strains of Burkholderia have not been clearly distinguished
from human pathogenic strains, which has lead to the need for the reassessment of the
risk of the registered Burkholderia strains for biological control (13). Analysis of the
molecular mechanisms will provide useful clues to developing biofungicides instead of
using living bacterial cells.
The LuxR-type regulatory genes are frequently identified in bacterial genomes
(4,10). The LuxR/FixJ regulator family (PROSITE documentation: PDOC00542) consists
of bacterial regulatory proteins that contain DNA-binding helix-turn-helix (HTH)
domains at their C termini (8). Based on their functional mechanisms, these LuxR type
proteins are grouped into two major subfamilies: response regulators and autoinducerbinding regulators (8). The response regulator subfamily includes the response regulators
within two-component signal transduction systems, such as FixJ (2), and these proteins
have a receiver domain, which is referred to as the acid pocket with highly conserved
acidic residues in the N termini (14). The other subfamily is composed of autoinducerbinding regulators, such as LuxR, with seven highly invariant residues (5). These LuxR
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type regulators control a wide variety of biological functions (8), including production of
secondary metabolites (10).
Burkholderia contaminans strain MS14 was isolated from a disease-suppressive
soil and showed a broad range of antifungal activities to plant and human pathogens (12).
A 22.7-kb genomic DNA fragment harboring six open-reading frames (ORFs) including
a LuxR type regulatory gene ambR2 is involved in biosynthesis of an antifungal
oligopeptide in strain MS14 (7). In this study, further sequence analysis revealed the
presence of another LuxR type regulatory gene, named ambR1, and three additional
ORFs. The roles of ambR1 in expression of the antifungal activity of MS14 were
investigated.
Materials and methods
Bacterial strains, plasmids and culture conditions
The bacterial strains and plasmids used in this study are listed in Table 3.1.
Burkholderia strains were cultured at 28°C on nutrient broth–yeast (NBY) extract agar
medium (22). Potato dextrose agar (PDA, Difco, Detroit, MI) was used for plate
bioassays of Burkholderia strains to evaluate antifungal activities. Antibiotics (Sigma
Chemical Co., St. Louis, MO) were added to media at the following concentrations:
trimethoprim (50 µg mL-1) and kanamycin (100 µg mL-1 for E. coli and 300 µg mL-1 for
Burkholderia strains, as needed).
Genomic library screening and sequencing
To identify more genes associated with the production of antifungal compound of
strain MS14, the fosmid 3C6 was identified from the MS14 genomic library using the
0.4-kb PCR product from pSL615 as described previously (7). DNA inserts of fosmids
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5F12 (7) and 3C6 were sequenced using a random shotgun approach (20). At least triple
coverage of sequencing reactions was achieved, and the Lasergene software package
(DNASTAR, Inc., Madison, WI) was used for generation of consensus sequences and
multiple sequence analysis. InterProScan program was used for prediction of functional
domains of proteins (16). NRPSpredictor was used for specificity prediction of
adenylation domains in nonribosomal peptide synthetases (NRPSs) (17). Phylogenetic
analyses were conducted in MEGA4 (21).
Bioassay for antifungal activities
B. contaminans strain MS14 and its mutants used in this study were evaluated for
antifungal activities against Geotrichum candidum F-260 (6) using the PDA plate
bioassays described previously (7). Three replicates for the plate bioassays were
performed independently.
Random mutagenesis
To characterize additional genes dedicated to antifungal activity, the mutant
MS14MT16 (Table 3.1) was generated and plasmid pSL616 was obtained using an EZTn5 <R6Kγori/KAN-2>Tnp Transposome kit (Epicentre Biotechnologies, Madison, WI)
as described previously (7).
Site-directed mutagenesis of the ambR1 gene and plasmid construction for
complementation assays
The wild-type ambR1 gene was disrupted by the insertion of a kanamycin cassette
into its ORF as described previously (10). A 4-kb PstI fragment of fosmid 5F12 carrying
ambR1 was cloned into pBluescript II SK (Strategene, La Jolla, CA) resulting plasmid
pGG4. Plasmid pGG4 was partially digested by BamHI, blunted by T4 DNA
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polymerase, and religated to remove the BamH1 restriction endonuclease site of
pBluescript II SK, resulting plasmid pGG5. A 1.1-kb BamH1 fragment of plasmid
pBSL15 (1), which carries nptII without a transcriptional terminator, was inserted into the
BamH1 site of plasmid pGG5, which is located in the frame of ambR1, generating
plasmid pGG6. A 5-kb PstI fragment of plasmid pGG6 harboring the ambR1 gene
disrupted by insertion of nptII was cloned into pBR325 (15) at the PstI site to generate
pGG7.
Mutagenesis of the ambR1 gene was conducted via a marker exchange procedure
as described previously (10), resulting in the generation of the mutant MS14GG44 (Table
3.1). Southern blotting analysis and PCR were used to verify the double crossover
mutants.
Plasmid pGG10 carrying the intact ambR1 gene was constructed for a
complementation assay of the mutant MS14GG44(ambR1::nptII). A 1.5-kb EcoR1
fragment carrying the intact ambR1 gene of pGG4 was inserted into expression vector
pMLS7 (9) to generate pGG10 for complementation assays. The empty vector pMLS7
was used as a control.
Constitutive expression of the ambR2 gene in mutants MS14MT15 and MS14GG44
The intact ORF of ambR2 was amplified using primers Eamb2F with BamHI and
Eamb2R with HindIII (Table 3.3) following a routine PCR method (18), and the product
(1 kb) was ligated into pGEM T-Easy vector (Promega Corporation, Madison, WI) to
generate pGG11. The 1-kb DNA fragment containing the intact ambR2 gene in pGG11
was digested by BamHI and HindIII, and cloned into expression vector pMLS7 to
generate pGG14. Plasmid pGG14 was electroporated into cells of mutants MS14MT15
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and MS14GG44, respectively. Trimethoprim and kanamycin resistance colonies were
confirmed to contain pGG14 by plasmid extraction and sequencing. Plate bioassays were
used to evaluate the antifungal activity of the resulting cells.
Quantitative real-time PCR
To measure effects of mutations in ambR1 and ambR2 on the ORFs present in the
genetic locus, transcription of the ORFs were analyzed using quantitative real-time PCR
(Q-PCR) as described previously (4,7).
Results
Sequence analysis of the flanking regions of the 22.7-kb genomic DNA fragment
The flanking regions of the previously described 22.7-kb genomic fragment (7)
were sequenced, revealing additional genes required for the production of antifungal
compound. The assemblage of sequencing reads formed two contigs, which generated
two consensus sequences flanking the 22.7-kb fragment: 3 kb downstream of the ambR2
gene and 19.5 kb upstream of the ORF6. In combination of the 22.7 kb sequence, totally
45.2-kb genomic DNA fragment was sequenced and deposited into GenBank with the
accession number: EU938698. The ambR1 gene was identified in the 3-kb region, which
is located downstream of ambR2 and has an opposite transcriptional orientation to ambR2
(Fig. 3.1). The ambR1 gene was predicted to encode a LuxR type regulator (273 a.a.) and
shared the highest similarity to bamb_6466 of B. ambifaria AMMD (GenBank accession
number: NC_008392) (Table 3.2). Interestingly, no homolog to bamb_6467, a
hypothetical protein located between bamb_6466 and bamb_6468 (the ambR2 homolog)
in the AMMD genome, was identified between ambR1 and ambR2. Additionally, a
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partial ORF (ORF1) downstream of ambR1 was predicted to encode the N terminus of a
FAD linked oxidase domain-containing protein.
Three new ORFs (ORFs 7, 8, and 9) were identified upstream of ORF6 in the
19.5-kb flanking region (Table 3.2). Organization and orientations of the three ORFs are
the same as those of the AMMD genome with an averaged amino acid identity of 91%
(Fig. 3.1; Table 3.2). ORF7 was predicated to encode a NRPS (1306 a.a.) and to contain
one module to catalyze the incorporation of an aromatic amino acid. The putative protein
(538 a.a.) from ORF8 was predicted to contain a beta-lactamase domain. Interestingly,
ORF9 was predicted to encode a multiple-domain protein (4469 a.a.). A beta-ketoacyl
synthetase domain was found in the N terminus, and a NRPS module was identified in
the C terminus, which was predicted to catalyze the incorporation of serine. Sequence
analyses of pSL616 revealed the transposon in the mutant MS14MT16, which was
defective in antifungal activity (Fig. 3.2), was located between nucleotides 9985-9986 of
ORF9 relative to its translational start codon (Fig. 3.1). These data indicate that ORF9
might be involved in production of the oligopeptide in strain MS14.
The AmbR1 and AmbR2 proteins were predicted to be distinctive members of the
LuxR family
A striking feature of this genetic region is the presence of two LuxR family
regulatory genes, which are located adjacent to one another (Fig. 3.1). Blast search
showed AmbR1 and AmbR2 proteins shared the highest amino acid similarities to the
LuxR regulatory proteins, such as SyrF (42% and 33%, respectively) that is a
transcriptional regulator crucial for syringomycin production in Pseudomonas syringae
pv. syringae (10). The deduced AmbR1 protein exhibited 36% identity to AmbR2. The
HTH DNA binding domains were identified at the C termini of AmbR1 and AmbR2.
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Neither autoinducer-binding domain nor response regulatory domain was found in the
two protein sequences using the InterProScan program (16), which indicates that AmbR1
and AmR2, like SyrF (10), may have different regulatory mechanisms from current
members of the LuxR/FixJ protein family.
Effect of mutation in ambR1 on antifungal activity
A nonpolar mutation was constructed by insertion of an nptII cassette into BamHI
of ambR1, and the mutant MS14GG44 was generated by marker exchange mutagenesis.
The mutant exhibited almost negligible antifungal activity towards G. candidum
(inhibitory zone radius ± SEM: 0.33 ± 0.33 mm) (Fig. 3.2), which is similar to the
mutants MS14MT13, MS14MT18 (7), and MS14MT16 (Fig. 3.1). As expected, the
wild-type strain MS14 showed a strong inhibition to the fungus (13.00 ± 0.58 mm). The
wild-type level of antifungal activities against G. candidum was observed for MS14GG44
complemented in trans with plasmid pGG10 (12.67 ± 0.33 mm), while the introduction
of the empty vector pMLS7 did not affect the phenotype of MS14GG44 (Fig. 3.2). These
results reveal the essential role of ambR1 in the expression of antifungal activity of strain
MS14.
Functional ambR1 and ambR2 were required for transcription of all the ORFs
except ORF1
To test whether the mutation in ambR1 affected transcription of the ORFs, Q-PCR
analyses were performed with RNAs isolated from strain MS14 and the mutant
MS14GG44. As expected, significant differences (P < 0.05) of expression levels of
ORFs 2-9 in the mutant MS14GG44 were observed as compared with those in the wildtype strain MS14. Transcript levels of the ORFs in mutants MS14GG44 were reduced
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13.2 fold on average (Fig. 3.3A). A previous study demonstrated that ambR2 positively
regulated transcription of ORFs 2-6 (7). As expected, expression levels of ORFs 7, 8 and
9 in the mutant MS14MT15 were significantly reduced 27.2 fold on average as compared
to strain MS14 (Fig. 3.3B). In contrast, transcription of ORF1 was not significantly
affected by mutations in either ambR1 or ambR2, indicating that the ORF is not regulated
by either of them. These data reveal that ambR1 and ambR2 gene products act to
promote, either directly or indirectly, transcription of ORFs 2-9.
Regulatory relationship of AmbR1 and AmbR2
To test the relationship between the two regulators, the transcriptional levels of
the ambR1 and ambR2 genes in strain MS14 and the mutants MS14GG44 and
MS14MT15 were measured by Q-PCR (Fig. 3.3C). The RNA level of ambR2 in mutant
MS14GG44 was significantly reduced 25 fold as compared with MS14. The full
expression of ambR2, which was equivalent to levels in MS14, was restored when
plasmid pGG10 containing the intact ambR1 gene was introduced into cells of mutant
MS14GG44. In contrast, no significant difference (P < 0.05) of transcription of ambR1
was observed among strains MS14, MS14MT15, and MS14MT15[pGG2]. These data
demonstrate that a functional ambR1 gene is essential for transcription of the regulator
gene ambR2, while ambR2 has no effect on the transcription of ambR1.
The intact ambR1 gene regulated by the S7 ribosomal protein promoter (9) in
plasmid pGG14 was transformed into the mutants MS14MT15 and MS14GG44, and
expressed constitutively. As expected, the strain MS14MT15[pGG14] resulted in
recovery of the antifungal activity against G. candidum to the wild-type level (Fig. 3.2).
However, the strain MS14GG44[pGG14] did not restore its antifungal activity. These
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results suggest that constitutive expression of ambR2 could not restore the function of
ambR1 in the production of the antifungal activity and both ambR1 and ambR2 have
direct regulatory roles for the activity.
Discussion
The crucial function of the ambR1 regulatory gene in production of antifungal
activity of strain MS14 is attributed to the following factors. First, the antifungal activity
of the ambR1 mutant MS14GG44 was eliminated while the ambR2 mutant MS14MT15
was reduced approximately 80% (7), indicating that ambR1 plays a larger role than
ambR2 in production of the antifungal activity. Second, like ambR2, ambR1 positively
regulates transcription of ORFs 5, 6, 7 and 9, which were predicted to encode putative
NRPSs that are required for antifungal activity of strain MS14. Both functional ambR1
and ambR2 genes are required for a full expression of ORF4, which codes for a putative
cyclic peptide transporter and is believed to be responsible for the secretion of the
oligopeptide. Third, the ambR1 gene controls transcription of ambR2 and constitutive
expression of ambR2 cannot restore the ambR1 phenotype. This suggests that ambR1 is
not only located at a higher position in a regulatory cascade, but also plays a direct role in
regulation of the production of the antifungal activity. Such a regulatory relationship of
ambR1 and ambR2 is the same as that of salA and syrF (10). It is predicted that the
ambR1 gene, like the salA regulatory gene in syringomycin and syringopeptin
production, encodes a major transcriptional regulator governing the whole gene cluster
for the production of the antifungal compound in MS14. In fact, in addition to the syrsyp genes, salA also regulates the production of another secondary metabolite, syringolin,
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whose biosynthesis genes are located outside the syr-syp gene clusters (11). It remains to
be explored if ambR1 is required for the production of other secondary metabolites.
The genes involved in production of NRPS oligopeptides are frequently clustered
in bacterial genomes and co-regulated by transcriptional factors (10,19). The conserved
ORF1 (partial) encodes the N terminus of a FAD linked oxidase domain-containing
protein and its transcription is not regulated by either ambR1 or ambR2, which implies
the gene may not be part of the gene cluster required for antifungal activity, and ambR1 is
the last gene at the left border of the gene cluster. Previous studies revealed that two
NRPS genes, which were predicted to catalyze four amino acids, were required for
antifungal activity of strain MS14 (7). In this study, two additional NRPS genes, which
were predicted to carry two catalytic modules, were characterized. The antifungal
oligopeptide is predicted by 2D NMR to contain eight amino acids (Smith, L. Lu, S.-E
and Gu, G., unpublished). Therefore, more genes involved in production of the
antifungal oligopeptide are expected to exist upstream of ORF9. Characterization of
these genes will be part of future efforts to further our understanding of this novel gene
cluster.
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Table 3.1

Bacterial strains and plasmids

Strains or plasmids

Relevant characteristics

Source

Escherichia coli
recA1, endA1, gyrA96, thi, hsdR17,
JM109

supE44, relA1, Δ(lac-proAB)/F' [traD36,

Promega

proAB+, lacIq, lacZΔM15]
Burkholderia contaminans
MS14

Wild type strain

(7)

MS14MT15

ambR2::Tn5 derivative of MS14; Kmr

(7)

MS14MT16

ORF9::Tn5 derivative of MS14; Kmr

This study

MS14GG44

ambR1::nptII derivative of MS14; Kmr

This study

Plasmid /fosmid
pSL615
pSL616
pBluescript II

EZ-Tn5 carrying the ~0.5 kb genomic DNA of
MS14MT15; Kmr
EZ-Tn5 carrying the ~8 kb genomic DNA of
MS14MT13; Kmr

(7)
This study

Cloning vector; Apr

Strategene

pBR325

Cloning vector; Cmr, Tcr, Apr

(15)

pMLS7

Expression vector of Burkholderia; Tpr

(9)

pGEM-T Easy

Cloning vector; Apr

Promega

pBSL15

Kanamycin resistance gene cassette; Kmr

(1)

SK

pGG2
pGG4
pGG5

pMLS7 carrying 2-kb PstI fragment
harboring the intact ambR2 gene; Tpr
pBluescript II SK carrying the 4 kb Pst1
fragment of 5F12 containing ambR1; Apr
pGG4 lacking the BamHI site of the
pBluescript II SK ploylinker; Apr
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(7)
This study
This study

Table 3.1 (continued)
pGG6

pGG5 with the nptII insertion in ambR1; Kmr,
Apr

This study

pBR325 carrying the 5-kb Pst1 fragment
pGG7

containing ambR1 disrupted by nptII; Cmr,
r

This study

r

Tc , Km
pGG10
pGG11

pMLS7 carrying 1.5-kb EcoRI fragment
harboring the intact ambR1 gene; Tpr
pGEM-T Easy carrying 1-kb PCR product
containing the intact ambR2 gene; Apr

This study
This study

pMLS7 carrying 1-kb BamHI and HindIII
pGG14

fragment containing the intact ambR2 gene;

This study

Tpr
5F12
3C6

pCC1FOS carrying 40-kb genomic DNA of
MS14; Cmr
pCC1FOS carrying 40-kb genomic DNA of
MS14; Cmr

(7)
This study

* Kmr: Kanamycin resistance; Apr: Ampicillin resistance; Tpr: trimethoprim
resistance; Cmr: Chloramphenicol resistance
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Table 3.2

The putative genes identified from the flanking regions of the 22.7-kb
genomic DNA fragment

Gene or

Size

ORF

(bp)

Homolog a

Identity
(%)

Predicted Function b
FAD linked oxidase domain

ORF1(partial) 1175
ambR1

822

bamb_6465

93

bamb_6466

89

protein
LuxR-type regulator
Nonribosomal peptide

ORF7

3921

bamb_6474

90

synthetase
Beta-lactamase domain

ORF8

1617

bamb_6475

93

protein
Beta-ketoacyl synthetase and

ORF9

13410

bamb_6476

90

Nonribosomal peptide
synthetase

a: Homolog to the putative proteins of Burkholderia ambifaria AMMDT (GenBank:
NC_008392); b: Predicted functions are based on the annotation of strain AMMD.
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Table 3.3

Primers used in this study

Primer
Sequence
ORF1F
5'-TCACGATCCGCTTGACGAGAT
ORF1R
5'-CAGCAAGCCGTTCCTGTCG
AmbR1F 5'-GGGCGGCGGATTTCAGTG
AmbR1R 5'-GAGCGGCAGCAGCGTATC
AmbR2F 5'-CCGCGGCGATCAGGTTGTA
AmbR2R 5'-CATGGAGTTCAGCAGATTGTTCGC
ORF2F
5'-GACTTTCATGCAGGCATAGGAGGG
ORF2R
5'-GATGATCGCCAGACGCTGTTGC
ORF3F
5'-CGGCGACGCGATTTCACTG
ORF3R
5'-CGGGGATTGCTTTCGATGCTG
ORF4F
5'-GAAGTGATACGCGCCCAGGAAC
ORF4R
5'-CATCTCGCCGCGGTGAAACA
ORF5F
5'-GTCGGTGACCAGCACGTTATTGT
ORF5R
5'-GTGCGTGCTGCTTCAGGTTGTT
ORF6F
5'-ACCCGTCGAGCAGGATGTGGT
ORF6R
5'-CGCGGCTTCGACTTTACCC
ORF7F
5'-GTCGGTGACCAGCACGTTATTGT
ORF7R
5'-GTGCGTGCTGCTTCAGGTTGTT
ORF8F
5'-ACCCGTCGAGCAGGATGTGGT
ORF8R
5'-CGCGGCTTCGACTTTACCC
ORF9F
5'-TCGCGGTTGTAGTGCCAGGTC
ORF9R
5'-CCGGTGCGCTTCAACTATCTCG
RecAF
5'-AAGATCGGCCAGGGCAAGGA
RecAR
5'-ACCATCGGGCATCGTGACCA
* Underlined letters represent restriction endonuclease sites.
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Source
This study
This study
This study
This study
(7)
(7)
(7)
(7)
(7)
(7)
(7)
(7)
(7)
(7)
(7)
(7)
This study
This study
This study
This study
This study
This study
(7)
(7)

Figure 3.1

Map of a 45.2-kb genomic region on the chromosome of Burkholderia
contaminans MS14.

The positions and orientations of the known genes and potential ORFs are shown as
horizontal arrows. The discontinuous arrow represents a partial ORF. Vertical arrows
and the flag indicate the insertion positions of the Tn5 transposon and the nptII cassette,
respectively. The open and solid vertical arrows/flag represent reduction and
elimination of antifungal activity, respectively.
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Figure 3.2

Plate bioassays for antifungal activities of Burkholderia contaminans
MS14 and its mutants.

Potato dextrose agar plates were inoculated with each of the strains and incubated for 3
days at 28oC. The plates were oversprayed with the indicator fungus Geotrichum
candidum and further incubated overnight. A: The wild-type strain MS14; B:
MS14MT16(ORF9::Tn5); C: MS14MT15(ambR2::Tn5); D: MS14MT15 [pGG14]; E:
MS14GG44(ambR1::nptII); F: MS14GG44 [pGG10]; G: MS14GG44 [pGG14]; and H:
MS14GG44 [pMLS7].
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Figure 3.3

Relative transcription of the ORFs identified in the 45.2-kb genetic DNA
fragment.

Transcript levels of the tested ORFs are presented relative to those in the wild-type strain
MS14. The CT values of tested ambR1 and ambR2 genes and the other ORFs were
corrected by the housekeeping gene recA as follows: ΔCT = CT(tested) – CT(recA). The
relative quantification (RQ) values were calculated by the formula RQ = 2[ΔCT(mutant) – ΔCT(wild
type)]
. Three replicates of Q-PCR were conducted independently. Vertical bars indicate
standard error of the means. A: Effect of the ambR1 mutation on transcription of the
ORFs identified. B: Effect of the ambR2 mutation on transcription of the newly
identified ORFs from the flanking regions of the 22.7 kb fragment. C: Effect of
mutations in ambR1 and ambR2 on transcription of the two genes: a, MS14; b,
MS14GG44(ambR1::nptII); c, MS14GG44[pGG10]; d, MS14MT15(ambR2::Tn5); e,
MS14MT15[pGG2].
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CHAPTER IV
CHARACTERIZATION OF THE RIGHT BORDER OF THE OCC GENE CLUSTER
ASSOCIATED WITH THE ANTIFUNGAL ACTIVITY OF BURKHOLDERIA
CONTAMINANS STRAIN MS14
Introduction
Burkholderia bacteria, which distribute widely in nature, are reported to be
important for the plant growth promotion (4). However, taxonomic distinctions have not
enabled biological control strains to be clearly distinguished from human pathogenic
strains, which has lead to the reassessment of the risk of the registered Burkholderia
strains as biological control agents (24). For example, some strains of B. contaminans
were isolated from sputum and blood samples of debilitated patients such as cystic
fibrosis patients (34), and some of them showed significant antifungal activity (11).
Analysis of the genomic structures and molecular mechanisms will benefit the
development of safer biologically based management and eliminate the potential
harmfulness the living bacteria may bring.
Till now, the whole genomic sequences of 22 strains of Burkholderia are
available in NCBI (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). According to the
annotation of the ExPASy Proteomics Server, eight of them are human pathogens
including three strains of B. cenocepacia, three strains of B. pseudomallei and two strains
of B. mallei. B. cenocepacia is the opportunistic pathogen of human cystic fibrosis or
chronic granulomatous diseases (22). B. pseudomallei and B. mallei are the causal agents
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of melioidosis and glanders diseases, respectively (3,15). The human pathogenesis of
two strains, B. ambifaria AMMD and B. multivorans strain ATCC17616, is still
unknown. The other 12 strains were considered to be not relative to the human
pathogenesis, such as B. lata strain 383 (http://www.expasy.ch/sprot/
hamap/BURM1.html).
Nonribosomal peptide synthetase (NRPS) and polyketide synthetase (PKS) are
large multimodular enzymes, which are involved in natural product synthesis in many
microorganisms (5). NRPS, involved in the biosynthesis of oligopeptide, is grouped by
active sites termed modules, in which each module is required for catalyzing one single
cycle of product length elongation. The order and number of the modules of an NRPS
protein are mainly followed by the “collinearity rule” (10). There are three main domains
in each module: the adenylation (A) domain, responsible for amino acid recognition and
adenylation at the expense of ATP; the thiolation (T) domain, carrier of thioesterified
amino acid intermediates; and the condensation (C) domain, catalyzing peptide bond
formation between two consecutive amino acids (5). The epimerization (E) domain as
one of the modification domains catalyzes the conversion of L-amino acids to their Disomers (23). Cyclization and release of the peptide product are catalyzed by the Cterminal thioesterase (Te) domain (29). Polyketide synthetases are a family of enzymes
or enzyme complexes that produce polyketides, a large class of secondary metabolites, in
bacteria, fungi, plants, and a few animals lineages (16). The biosyntheses of polyketides
share striking architectural and organizational similarities with nonribosomal peptide
biosynthesis, and their modules can be integrated to produce the hybrid NRPS-PKS
products. Some pharmaceutical antimicrobial agents, such as the precursor of penicillin
and erythromycin, are synthesized through these mechanisms (6,33).
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ATP-binding cassette (ABC) transporters are a large superfamily of integral
membrane proteins that carry various substrates across cellular membranes, which are
involved in the export or import of a wide variety of substrates ranging from ions to large
polypeptides (14). Extensive studies showed ABC transporters are one of major groups
of secretion machinery associated with transportation of bacterial secondary metabolites,
such as drugs and antibiotics (7).
B. contaminans strain MS14 showing a broad range of antifungal activities to
plant and animal pathogens was isolated from a disease-suppressive soil (21). Production
of an octapeptide, named as occidiofungin, is responsible for the antifungal activities of
strain MS14 (19). Occidiofungins, composed of eight amino acids, are two structurerelated antifungal compounds, with the masses of 1119.5 and 1215.5 Da, respectively
(Fig. 4.2a). A 45.2-kb genomic DNA fragment harboring 11 open-reading frames
(ORFs) including the bisoythetase genes occA, occB, occC, and occD, two LuxR
regulatory genes ambR1 and ambR2, and the ABC transporter gene occT (11,12) was
identified. Analysis of transcription demonstrated that both ambR1 and ambR2 are
essential for the expression of all the ORFs except for ORF1 and the production of the
antifungal activity. In this study, the right border of the occ gene cluster was sequenced,
and further sequence analysis revealed the presence of another seven additional ORFs,
which included ORF11(occE), another NRPS gene, and ORF15, a putative thioesterase.
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Materials and Methods
Bacterial strains, plasmids and culture conditions
The bacterial strains and plasmids used in this study are described in Table 4.1.
Escherichia coli strain JM109 was grown in Luria-Bertani medium at 37°C (28).
Burkholderia strains were cultured at 28°C on nutrient broth–yeast (NBY) extract agar
medium (35). When required, antibiotics were added at the following concentrations:
ampicillin (100 µg ml-1), trimethoprim (50 µg ml-1), chloramphenicol (12.5 µg ml-1), and
kanamycin (100 µg ml-1 for E. coli and 300 µg ml-1 for the MS14 mutants).
Bioassay for antifungal activities
B. contaminans strain MS14 and its mutants used in this study were evaluated for
antifungal activities against Geotrichum candidum F-260 using potato dextrose agar
(PDA, Difco, Detroit, MI) plate bioassays described previously (11). Three replicates for
the plate bioassays were performed independently.
Random mutagenesis, genomic library screening and sequencing
To identify more genes associated with production of antifungal compound of
strain MS14, the mutant MS14MT24 (Table 4.1) was generated and plasmid pSL604 was
obtained using an EZ-Tn5™ <R6Kγori/KAN-2>Tnp Transposome™ Kit (Epicentre
Biotechnologies, Madison, WI) as described previously (11). Fosmid 4G5 was identified
from the MS14 genomic library using the 1-kb PCR product from pSL624 as described
previously (11). DNA inserts of fosmid 4G5 was sequenced using a random shotgun
approach (31). At least triple coverage of sequencing reactions was achieved, and the
Lasergene software package (DNASTAR, Inc., Madison, WI) was used for generation of
consensus sequence. Bacterial ORFs were subsequently predicted by the Softberry
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FGENESB program (Softberry, Inc., Mount Kisco, NY), and the identified ORFs were
analyzed using Blastx in the NCBI database. Putative promoter sequences were
identified by the Softberry BPROM program. The InterProScan program was used for
prediction of functional domains of proteins (26). NRPSpredictor (27) and the NPRSPKS web-based software (2) were used for specificity prediction of adenylation domains
in nonribosomal peptide synthetases (NRPSs). The program “IslandPick” was used to
analyze the sequence characteristics as genomic islands (17).
RNA extraction and quantitative real-time PCR
Total RNA of strain MS14 and its mutants were extracted using an RNeasy
Protect Bacteria kit (Qiagen, Valencia, CA) as recommended by the manufacturer.
Transcription of the ORFs was analyzed using quantitative real-time PCR (Q-PCR) as
described previously (10,11). Three replicates of Q-PCR were conducted independently,
and statistical significant differences were determined for the log values of relative
quantification by analysis of variance (P < 0.05) followed by the Bonferroni and Dunnet
post hoc multiple comparisons (ANOVA, SAS Institute, Inc., NC, USA).
Site-directed mutagenesis of the genes occT, occE and ORF15
The wild-type occT, occE and ORF15 genes were disrupted by the insertion of a
kanamycin cassette into their open reading frames, respectively, as described previously
(20). Plasmids pBR325 and pBSL15 were digested by EcoRI, blunted by T4 DNA
polyermerase, and self ligated to generate plasmids pBR325[R1] and pBSL15[R1]
without EcoRI (Table 4.1) (1). To mutate occT, the 2.1-kb fragment of the occT gene of
strain MS14, obtained by PCR using the primers MoccTF containing the HindIII site and
MoccTRA with the EcoRV site (Table 4.3), was digested with HindIII and EcoRV and
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inserted into pBR325[R1], resulting in plasmid pGG25. A 1.1-kb EcoRI fragment
containing the nptII gene without a transcriptional terminator from pBSL15 was inserted
into pGG25 at the EcoRI site, which is located in the frame of occT, to disrupt
transcription of occT, resulting in pGG26. Mutagenesis of the occT gene was conducted
via a marker exchange procedure as described previously (20), to generate the mutant
MS14SL16 (Table 4.1). PCR analysis and sequencing were used to verify the double
crossover mutants. Mutations of occE and ORF15 were generated using a similar
mutagenesis strategy. The 4-kb and 1-kb fragments of the occE and ORF15 genes,
obtained by PCR using two pairs of primers MoccEF and MoccER (for occE), MORF15F
and MORF15R (for ORF15, Table 4.3), were cloned into the pGEM-T Easy Vector
System I (Promega Corporation, Madison, WI) resulting in plasmids pGG20 and pGG15.
The nptII gene was inserted into pGG20 at BamHI and pGG15 at SmaI, generating
plasmids pGG21 and pGG16, respectively. The 5-kb EcoRI fragment of pGG21
harboring the occE gene disrupted by insertion of nptII was cloned into pBR325 (25) at
the EcoRI site to generate pGG22. The 2-kb EcoRI fragment of pGG16 harboring the
ORF15 gene disrupted by insertion of nptII was cloned into pBR325 (25) to generate
pGG17. Mutagenesis of the occE and ORF15 genes were conducted to generate the
mutants MS14GG78 and MS14GG82, respectively, with the marker exchange as
described above.
Complementation of occE mutant MS14GG78
To obtain the intact wild type gene occE, which was disrupted in the mutant
MS14GG78, a 4.5-kb fragment was amplified by PCR using primers EoccEF and
EoccER, both of which contain the HindIII site (Table 4.3), and cloned into the pGEM-T
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Easy Vector, resulting in the plasmid pGG23. The presence of the intact occE gene in the
4.5-kb DNA fragment was verified by sequencing. The 4.5-kb HindIII fragment
harboring the intact occE gene was inserted into the Burkholderia gene expression vector
pMLS7 (18), to generate the plasmid pGG24. The plasmid pGG24 were electroporated
into cells of the mutant MS14GG78, an occE mutant (Table 4.1). Colonies acquiring the
trimethoprim resistance were confirmed to contain the plasmid construct pGG24 by
plasmid extraction and restriction enzyme digestion. Complementation experiments were
conducted using the plate assays to evaluate antifungal activity against G. candidum as
described previously (11).
Results and discussion
Sequence analysis of the right border of the occ gene cluster
The upstream region of ORF9 of the previously described 45.2-kb genomic
fragment (12) was sequenced through the sequencing of the fosmid 4G5, and seven new
ORFs (ORFs 10-16) were identified in this region (Fig. 4.1; Table 4.2). In combination
of the 45.2-kb sequence, a totally 58.2-kb genomic DNA fragment, named as the occ
gene cluster, was obtained and deposited into GenBank with the accession number:
EU938698. Organization and orientations of the ORFs 10-15 are the same as those of the
B. ambifaria strain AMMD genome with an averaged amino acid identity of 91%, and
ORF16 has the highest similarity (93%) to its homolog C7511 of B. lata strain 383 (Fig.
4.1; Table 4.2), while its homolog was not found in the genome of strain AMMD with
BLAST. The putative protein (1107 a.a.) from ORF10 was predicted to encode a shortchain dehydrogenase. ORF11 (occE) was predicated to encode a NRPS (1475 a.a.) and
to contain the first module to catalyze Asn (BHN1) amino acid of occidiofungin (Fig.
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4.2). ORFs 12, 13, and 14 were predicted to encode oxygenase, transaminase and
epimerase respectively. Putative protein sequence of ORF15 is 219 amino acids in length
and carries a Te domain. Sequence analysis of pSL624 revealed the transposon in the
mutant MS14MT24 defective in antifungal activity (Fig. 4.4) was located between
nucleotides 12982-12983 of ORF9 relative to its translational start codon (Fig. 4.1).
Putative promoters were identified at the upstream of ORF1, ambR1, ORF13 and ORF16
and their locations are shown in Fig. 4.1.
Sequence analysis revealed that the occ gene cluster, excluding ORF1 and
ORF16, only shared high similarity (99% nucleotide coverage and 91% identity) to an
uncharacterized DNA region of B. ambifaria strain AMMD. The gene cluster was not
found in other Burkholderia strains available in GenBank (nucleotide coverage < 24%),
including some identified opportunistic human pathogens B. cenocepacia strain J2315,
AU1054, HI2424, B. pseudomallei strain 668, 1710b, 1106a, and B. mallei strain NCTC
10247, NCTC 10229. The sequences of the flanking regions of the occ gene cluster in
strain MS14 share highest identities (89% nucleotide identity) with the homologs C7522
(left) and C7511 (right) in chromosome 3 of B. lata 383. The average G+C content of the
occ gene cluster is 67.74%, which is closer to those of flanking region sequences in
strain AMMD (left: bam_6475, 68.5% and right: bam_6483, 65.89%) but different from
those of strain MS14 (55.16% left and 61.81% right). Besides, sequence analysis of the
program “IslandPick” indicated that the uncharacterized exclusive homolog of the occ
gene cluster in strain AMMD possessed the characteristics as a genomic island. These
data suggest that the occ gene cluster, as a potential genomic island, may be horizontally
transferred from a strain similar to B. ambifaria AMMD and integrated into a strain
similar to B. lata 383. More importantly, the absence of the gene cluster in clinical
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strains of Burkholderia indicated that occidiofungin, the antifungal compound produced
by the occ gene cluster of strain MS14, is not involved in the potential human
pathogenesis. This finding has provided insights for the usage of occidiofungin, and
clues for development of pharmaceutical medicines and agricultural fungicides.
Functional analysis of the occidiofungin synthetases
Based on the analogy to the known NRPSs, OccA, OccB, OccC, OccD, and OccE
were predicted to be composed of two (8 and 7), two (6 and 5), one (4), two (3and 2), and
one (1) modules, respectively (Fig. 4.2b). A detailed analysis of OccA - OccE revealed
that the six modules encoded by OccA, OccB, OccC, OccD and the first module of OccE
have in common the three major domains known as the condensation, adenylation, and
thiolation domains. Among the eight amino acids of occidiofungain, Asn7 and Ser8
predicted to be catalyzed by OccA matched the prediction (Fig. 4.2). There were no
confirmed modular prediction for OccB and OccE, which were predicted to catalyze
Lys5, Gly6 and Ans1 (BHN1), all of them could find their corresponding homologs
through the NPRS-PKS web-based software. OccC is predicted to catalyze the addition
of Tyr-D with the 38% identity and 55% similarity. The C-terminal part of OccD is
predicted to catalyze the production of Ser with the highest identity of 54% and similarity
of 67%, or Trp with 40% identity and 55% similarity.
No match of amino acid substrate was found for the first half of the synthetase
OccD from the current NRPS database. According to the position of the novel amino
acid module 2 (NAA2) in the occidiofungin and the sequence characteristics of the occD
gene, the fragment encoding the modules for the production of NAA2 was located at the
N-terminal part of occD. The occD gene, which is essential for occidiofungin
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biosynthesis (see below), encodes a hybrid NRPS-PKS protein containing domains
characteristic of both NRPSs and PKSs. Residing at the N terminus of occD are two PKS
modules, which were predicted to synthesize two keto acids (malonate). To produce
NAA2, it is hypothesized that, the putative transaminase encoded by ORF13 transfers an
amino group to one of the keto acids for the formation of the novel amino acid. All of
these results indicated that occidiofungin might be produced through a novel hybrid
NRPS-PKS mechanism. Collectively, these genetic analyses basically match the
backbone structure of occidiofungin except for the No. 5 position of the oligopeptide.
Modifying genes for the production of occidiofungin
ORFs 12-15 in the left border of the occ gene cluster, were predicted to encode
four putative modification enzymes involving in production of occidiofungin. The
putative protein encoded by ORF12 as an oxygenase, was predicted to introduce one
atom of oxygen to Asn1 to form BHN1 or work for the formation of BHT4. ORF13, as a
transaminase, was predicted to transfers an amino group for the formation of NAA2.
Based on the analyses of NPRS-PKS web-based software, Tyr4 and Ser8 were predicted
to be D formation. None of the eight modules, however, in the occ gene cluster harbors
an internal E-domain for the conversion of the L to the D form, and the NAD-dependent
epimerase domain was identified at ORF14, which suggest that this external epimerase is
responsible for the conversion of the amino acid conformation L and D. Sequence
analysis revealed that two putative TE domains were located at ORF15 and the Cterminal region of occA, respectively, which were predicted to be important for the
termination and cyclization of the production of occidiofungin. The putative glycosyl

65

transferase encoded by ORF4, was predicted to catalyze the transfer of xylose for the
formation of NAA2 (11).
Disruption of the NRPS gene occE eliminated the antifungal activity of strain MS14
A nonpolar mutation was constructed by insertion of an nptII cassette into BamHI
of occE, and the mutant MS14GG78 was generated by marker exchange mutagenesis.
PCR analysis demonstrated that occE was disrupted by insertion of nptII in the genome
of the mutant. The mutant exhibited negligible antifungal activity towards G. candidum
(inhibitory zone radius ± SEM: 0.33 ± 0.33 mm), which is similar to the mutants
MS14MT13, MS14MT18 (11), MS14MT16 (12), and MS14MT24 (Fig. 4.4). As
expected, the wild-type strain MS14 showed a strong inhibition to the fungus (13.00 ±
0.58 mm). The wild-type level of antifungal activities against G. candidum was observed
for MS14GG78 complemented in trans with plasmid pGG24 (12.67 ± 0.33 mm). As
expected, the presence of the empty vector pMLS7 had no effect on antifungal activities
of either the wild type strain MS14 or the mutant MS14GG78 (data not shown). These
results further confirmed the essential role of occE in the production of antifungal activity
of strain MS14.
Mutagenesis of occT and ORF15 did not eliminate the antifungal function of strain
MS14
The occT mutant MS14SL16 and ORF15 mutant MS14GG82 were generated by
site directed mutagenesis. As compared to the wild type strain MS14 (inhibitory zone
radius ± SEM: 13.00 ± 0.58 mm), the antifungal activities of the two mutants were
significantly reduced, but not eliminated (MS14SL16: 8.24 ± 0.64 mm; MS14GG82: 8.79
± 0.38 mm) (Fig. 4.4).
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The putative protein encoded by the occT gene carries an ABC transmembrane
domain at N terminus and a ATP-binding cassette domain at C terminus, and belongs to
bacterial ABC transporter protein family (11). The mutation of the nptII insertion in
occT could not eliminate antifungal activity, indicating the gene may not be absolutely
required for secretion of occidiofungin. Disruption of occT decreased the secretion
amount of occidiofungin, but it might be exported via other pathways. In addition, ABC
transporters are conserved and common enzymes in bacteria, it was reported that there
are 338 ABC system-associated ORFs in B. pseudomallei strain K96243 and 275 ORFs
in B. mallei strain ATCC 23344 (13). It is hypothesized that a homolog(s) also exist in
the strain MS14 genomes, which complement the role of the occT gene in export of
occidiofungin in the mutant. For example, BLAST search found that there was another
homolog of occT (bam_1536, amino acid identity: 39%) in chromosome 1 of strain
AMMD, in addition to the homolog bam_6469 in chromosome 3.
The putative protein encoded by the ORF15 gene carries a Te domain, which was
predicted to be involved in cyclization and termination of oligopeptide produced by
NRPS. However, like occT, the mutation in ORF15 did not eliminate antifungal activity
of strain MS14. It is hypothesized that another Te domain, which located at the C
terminal of occA complemented the role of ORF15.
Transcription of all the seven ORFs identified in the region except ORF16 was
regulated by both ambR1 and ambR2, the LuxR-type regulatory genes
To test the relationship between the newly identified genes or ORFs with the
LuxR regulatory genes ambR1 and ambR2, Q-PCR analyses were performed with RNAs
isolated from strain MS14 and the mutants MS14GG44 and MS14MT15 (Table 4.1).
Previous studies demonstrated that both ambR1 and ambR2 positively regulated
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transcription of ORFs 2-9 (12). As expected, significant differences (P < 0.05) of
expression levels of ORFs 10-15 in the mutants MS14GG44 and MS14MT15 were
observed as compared with those in the wild-type strain MS14. Transcript levels of the
ORFs in mutants MS14GG44 and MS14MT15 were reduced 13.2 and 12.0 folds on
average, respectively (Fig. 4.3). These data suggest that transcription of ORFs 10-15 are
promoted by the ambR1 and ambR2 gene products.
Transcription of ORF16 was not significantly affected by mutations in either
ambR1 or ambR2, indicating that the ORF16 is not regulated by either of them. In
addition, the ORF16 gene, which codes for a hypothetically conserved protein, has
highest identity (93%) to ORF number of the of B. lata strain 383 genome ; however, no
significant homolog was found in the genome of strain AMMD, which has an
uncharacterized genomic region sharing the highest similarity to the occ gene cluster
(ambR1 - ORF15). These data implies that ORF16, similar to ORF1 (12), may not be
part of the gene cluster required for the antifungal activity of strain MS14, and ORF15 is
the last gene at the right border of the gene cluster. These results indicate that the whole
length of the occ gene cluster, which is responsible for the production of occidiofungin,
has been identified and it ranges from ambR1 to ORF15 (Fig. 4.1).
Conclusions
The right border of the occ gene cluster, required for the antifungal activity of
strain MS14, was sequenced and another seven putative genes were identified. Sitedirected mutagenesis revealed that occE (ORF11) was required for production of the
antifungal activity against the indicator fungus G. candidum. By contrast, ORF2 and
ORF15 were not absolutely required for the antifungal activity of MS14. Transcription
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of the six putative genes (ORFs 10-15) identified in the region except ORF16 was
regulated by the LuxR-type regulatory genes, ambR1 and ambR2. The whole length of
the occ gene cluster has been characterized, which is composed of 16 ORFs. Among the
16 members of this cluster, ORF5, 6, 7, 9 and 11 (OccA - OccE), which were predicted to
be NRPS or NRPS-PKS, are directly relative to the biosynthesis of the antifungal
compound occidiofungin. AmbR1 and AmbR2 are the regulators controlling the
transcription and expression of occidiofungin. ORF2 (OccT) is predicted to be relative to
the secretion of the antifungal compound. ORF4, 12, 13, 14 and 15 were predicted to be
involved in the modification of occidiofungin or its components. In addition, sequence
analysis indicated that occidiofungin produced by the occ gene cluster of strain MS14 is
not involved in the potential human pathogenesis. The genetic information of the occ
gene cluster has provided a solid foundation to enhance production of occidiofungin and
to optimize its chemical structure to increase its antifungal activity and to minimize
possible toxicity to plants and animals. For example, overexpression of occT and/or
ambR1 may increase occidiofungin production by strain MS14.
The study of hybrid NRP-PK natural products, which further expands the
perspective of combinatorial biosynthesis, is attracting more attentions recently (9).
Some hybrid products with medicinal importance have been reported, such as rapamycin,
bleomycin and leinamycin (8,30,32). Understanding the genomic structures for the
production of occidiofungin, especially the biosynthesis of the novel amino acid will
benefit the optimization and production of novel “unnatural” natural products.
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Table 4.1

Bacterial strains and plasmids

Strains or
plasmids

Relevant characteristics

Source

Escherichia
coli
recA1, endA1, gyrA96, thi, hsdR17, supE44,
JM109

relA1, Δ(lac-proAB)/F' [traD36, proAB+, lacIq,

Promega

lacZΔM15]
Burkholderia contaminans
MS14

Wild type strain

MS14MT15

ambR2::Tn5 derivative of MS14; Kmr

MS14GG44

(11)
(11)
r

ambR1::nptII derivative of MS14; Km

(12)

MS14MT24

r

ORF9::Tn5 derivative of MS14; Km

This study

MS14GG78

occE::nptII derivative of MS14; Kmr

This study

MS14GG82

ORF15::nptII derivative of MS14; Kmr

This study

MS14SL16

occT::nptII derivative of MS14; Kmr

This study

Plasmid /fosmid
pSL604
pBluescript II

EZ-Tn5 carrying the ~1 kb genomic DNA of
MS14MT24; Kmr

This study

Cloning vector; Apr

Strategene

pBR325

Cloning vector; Cmr, Tcr, Apr

(25)

pBR325[R1]

pBR325 without EcoRI site; Cmr, Tcr, Apr

SK

r

(25)

pMLS7

Expression vector of Burkholderia; Tp

(18)

pGEM-T Easy

Cloning vector; Apr

Promega

pBSL15

Kanamycin resistance gene cassette; Kmr

(1)

pBSL15[R1]

Kanamycin resistance gene cassette lacking
EcoRI sites; Kmr
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This study

Table 4.1 (continued)
pGG15
pGG16

pGEM-T Easy carrying 1-kb PCR product
containing the ORF15 gene; Apr
pGG15 with the nptII insertion in ORF15 at
the SmaI site; Kmr, Apr

This study
This study

pBR325 carrying the 2.1-kb EcoRI fragment
pGG17

containing ORF15 disrupted by nptII; Cmr,

This study

Tcr, Kmr
pGG20
pGG21

pGEM-T Easy carrying 4-kb PCR product
containing the occE gene; Apr
pGG20 with the nptII insertion in occE at the
BamHI site; Kmr, Apr

This study
This study

pBR325 carrying the 5-kb EcoRI fragment
pGG22

containing occE gene disrupted by nptII; Cmr,

This study

Tcr, Kmr
pGG23
pGG24

pGEM-T Easy carrying 4.5-kb PCR product
containing the intact occE gene; Apr
pMLS7 carrying 4.5-kb HindIII fragment
harboring the intact occE gene; Tpr

This study
This study

pBR325[R1] carrying the 2.1-kb HindIII pGG25

EcoRV PCR fragment containing occT gene;

This study

Cmr, Tcr
pGG26
4G5

pGG25 with the nptII insertion in occT at
EcoRI site; Cmr, Tcr, Kmr
pCC1FOS carrying 40-kb genomic DNA of
MS14; Cmr

This study
This study

* Kmr: Kanamycin resistance; Apr: Ampicillin resistance; Tpr: Trimethoprim
resistance; Cmr: Chloramphenicol resistance; Tcr, Tetracycline resistance
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Table 4.2
Gene or
ORF

The putative genes identified at the right border of occ gene cluster
Size (bp) Homologue a

Identity (%)

3324

bamb_6477

92

bamb_6478

91

Predicted Function b
Short-chain

ORF10

dehydrogenase

ORF11
4428
(occE)

Nonribosomal peptide
synthetase

Taurine catabolism
ORF12

987

bamb_6479

91
dioxygenase

ORF13

1371

bamb_6480

91

Transaminase

ORF14

951

bamb_6481

94

Epimerase / Dehydratase

ORF15

720

bamb_6482

90

Thioesterase

ORF16

288

C7511

93

Hypothetical protein c

a: Homolog to the putative proteins of Burkholderia ambifaria AMMD (GenBank:
NC_008392); b: Predicted functions are based on annotation of strain AMMD and
strain 383; c: homolog to C7511 of B. lata 383 (GenBank: NC_007509).
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Table 4.3

Primers used in this study

Primer

Sequence (5’-3’)

ORF10F

5'-GAGCGTCTGCAGGTTCGGATAGG

ORF10R

5'-TCTCGGCCTGGATTCGCTGGT

occEF

5'-CTTCCCGGCGCACTTCACAG

occER

5'-ATCGTCGCCGGCCGCAATCA

ORF12F

5'-GGAACAGATGGGCCTGATTGAAG

ORF12R

5'-AGCCTTCTGCGCGGATAACG

ORF13F

5'-CCGCATCACGGCTTCATTGAC

ORF13R

5'-CTCCTTCCCGCGGCTGTTTAC

ORF14F

5'-GCACGATGAAGTTGGACACG

ORF14R

5'-CGCCTGCTACGACGAAGG

ORF15F

5'-GCCATCGTTCGCATTTCGTTTC

ORF15R

5'-CAGGCTGGCGGTGGACATCA

ORF16F

5'-CGAGACCGGCTGGCATGTTCA

ORF16R

5'-CTGCGGGAAGTCGGGGCGTAT

MoccEF

5'-GTCCGGGGCAAACACGAAGTC

MoccER

5'-CTCCTTGGATTACGGGGCAGAC

MORF15F

5'-CGCCACCCGTTACGAGGATTC

MORF15R

5'-ACGCGTCCCCTCTTCCTACG

EoccEF*

5'-CCCAAGCTTATGCTTCCCGATACA

EoccER*

5'-CCCAAGCTTGCTTCTTGTAGTCAG

* Underlined letters represent restriction endonuclease sites.
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Figure 4.1

Map of 58.2-kb occidiofungin gene cluster of Burkholderia contaminans
strain MS14.

The positions and orientations of the known genes and potential ORFs are shown as
horizontal arrows. Vertical arrows and flags indicate the insertion positions of the Tn5
transposon and the nptII gene cassette, respectively. The open and solid vertical
arrows/flags represent reduction and elimination of antifungal activity, respectively. The
arrows indicate putative promoter sequence.
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Figure 4.2

Schematic representation of the amino acid modules present in occ gene
cluster.

Schematic representation of the amino acid modules present in occA – occE. (a) Primary
structure of occidiofungin. BHT, beta hydroxyl tyrosine; BHN, beta hydroxyl
asparagines; NAA, Novel amino acid. (b) Modular organization of the occ biosynthetic
genes. The individual amino acid residues are incorporated by module 1 to module 8 in a
collinear manner with the structure of the occidiofungin molecule. NRPS, nonribosomal
peptide synthetase; PKS, polyketide synthetase.
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Figure 4.3

Expression of the ORFs identified in the occ gene cluster in strain MS14
and its mutants.

Expression of the ORFs identified in the occ gene cluster in strain MS14 and its mutants
MS14MT15 and MS14GG44 (Table 4.1). Transcript levels of the tested ORFs are
presented relative to the transcript levels in the wild type MS14. Mean values for three
biological replicates are given, and error bars represent the standard errors of the means.
RQ, relative quantification.
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Figure 4.4

Plate bioassays of antifungal activities of Burkholderia contaminans strain
MS14 with its mutants.

Potato dextrose agar plates were inoculated with each of the strains and incubated for 3
days at 28oC. The plates were oversprayed with the indicator fungus Geotrichum
candidum and further incubated overnight. A: The wild-type strain MS14; B:
MS14GG78; C: MS14GG78 (pGG24); D: MS14MT24; E: MS14GG82; F: MS14SL16.
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